» Articles » PMID: 32324813

Early Life Exposures Associated with Risk of Small Intestinal Neuroendocrine Tumors

Overview
Journal PLoS One
Date 2020 Apr 24
PMID 32324813
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Small intestinal neuroendocrine tumors (SINT) are rare with incidence increasing over the past 40 years. The purpose of this work is to examine the role of environmental exposures in the rise of SINT incidence using the Utah Population Database, a resource of linked records including life events, cancer diagnoses and residential histories. SINT cases born in Utah were identified through the Utah Cancer Registry with: diagnosis years of 1948 to 2014 and age at diagnosis of 23 to 88 years. Controls were matched to cases 10:1 based on sex, birth year and residence time in Utah. Cases and controls were geocoded to their birth locale. An isotonic spatial scan statistic was used to test for the occurrence and location(s) of SINT clusters. Potential environmental exposures and economic conditions in the birth locales at the time of the birth (1883-1982) were generated using historical references. Conditional logistic regression was used to estimate odd ratios. We report a spatial cluster central to historic coal mining communities, associated with a 2.86 relative risk (p = 0.016) of SINT. Aspatial analyses of industry and mining exposures further suggest elevated risk for early life exposure near areas involved in the construction industry (OR 1.98 p = 0.024). Other exposures approached significance including coal, uranium and hard rock mining during the earliest period (1883-1929) when safety from exposures was not considered. We do observe a lower risk (OR 0.58 p = 0.033) associated with individuals born in rural areas in the most recent period (1945-1982). Environmental exposures early in life, especially those from industries such as mining, may confer an elevated risk of SINT.

Citing Articles

Observational methods for human studies of transgenerational effects.

Richards-Steed R, Wan N, Bakian A, Medina R, Brewer S, Smith K Epigenetics. 2024; 19(1):2366065.

PMID: 38870389 PMC: 11178273. DOI: 10.1080/15592294.2024.2366065.


Radioligand Therapy with [Lu]Lu-DOTA-TATE or [Lu]Lu-DOTA-TATE and [Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade.

Durma A, Saracyn M, Kolodziej M, Jozwik-Plebanek K, Dmochowska B, Mroz A Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765013 PMC: 10537132. DOI: 10.3390/ph16091205.


Genetic Drivers of Ileal Neuroendocrine Tumors.

Carpizo D, Harris C Cancers (Basel). 2021; 13(20).

PMID: 34680217 PMC: 8533727. DOI: 10.3390/cancers13205070.

References
1.
Mueller G, Clayton A, Zahnd W, Hollenbeck K, Barrow M, Jenkins W . Manuscript title: Geospatial analysis of Cancer risk and residential proximity to coal mines in Illinois. Ecotoxicol Environ Saf. 2015; 120:155-62. DOI: 10.1016/j.ecoenv.2015.05.037. View

2.
DiSario J, Burt R, Vargas H, McWhorter W . Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol. 1994; 89(5):699-701. View

3.
Curtin K, Cannon-Albright L, VanDerslice J, Yu Z, Herget K, Thota R . Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah. Cancer Epidemiol Biomarkers Prev. 2019; 28(12):1998-2004. PMC: 6961822. DOI: 10.1158/1055-9965.EPI-19-0465. View

4.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342. PMC: 5824320. DOI: 10.1001/jamaoncol.2017.0589. View

5.
Ou J, Hanson H, Ramsay J, Leiser C, Zhang Y, VanDerslice J . Fine Particulate Matter and Respiratory Healthcare Encounters among Survivors of Childhood Cancers. Int J Environ Res Public Health. 2019; 16(6). PMC: 6466161. DOI: 10.3390/ijerph16061081. View